leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PRESS RELEASE

...see all

Global Translational Regenerative Medicine Market Set To Grow To $61bn By 2022

Visiongain’ has launched a new pharma report Global Translational Regenerative Medicine Market Prospects 2018-2028: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Regenerative medicine has been undergoing a period of sustained innovation over the last two decades. Tissue engineering and stem cell research in particular have seen a level of interest which it hasn’t received for a long while. Novel cell sources such as induced pluripotent stem cells have also helped to open new areas of research which had previously seemed impossible due to limited resources. There are potential opportunities in the market for participating companies, however certain risks and limitations also abound. The global regulations surrounding regenerative medicine remains fragmented. The changes to regulatory processes in the leading national and regional markets should help to drive progress in the regenerative medicine market.

The lead analyst of the report commented “Growth in the global translational regenerative medicine market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.

Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will drive the growth in stem cell therapies.

Leading companies featured in the report include Alphatec Spine, Anterogen, Athersys, Avita Medical, AxoGen, Medipost, Mesoblast, NuVasive, Ocata Therapeutics, Organogenesis, Pharmicell, Regenerys, TiGenix, UniQure, Vericel Corporation

 

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close